Trending Topic

15 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Cardiovascular diseases are the most common cause of mortality and morbidity in adults worldwide.1 Coronary angiography (CAG) is the gold standard method for evaluating atherosclerotic coronary artery disease (CAD).2 It is conventionally performed via the trans-femoral (TF) route. Recently, however, the trans-radial (TR) route has become the preferred way.3 The TR route offers better procedure comfort, shorter hospitalization […]

Drug-eluting stents appear superior to bare metal stents for vein-graft PCI in vessels up to a stent diameter of 4 mm

Oliver P. Guttmann, Daniel A. Jones, Kassem A. Safwan, Sean Gallagher, Krishnaraj S. Rathod, Steve Hamshere, Elliot J. Smith, Ajay K. Jain, Anthony Mathur, Andrew Wragg, Charles J. Knight, Roshan Weerackody
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Aug 20th 2018 Heart International. 2016;11(1):e17-e24 DOI: https://doi.org/10.5301/heartint.5000228
Select a Section…
1

Abstract

Overview

Background. Research trials have shown improved short-term outcome with drug-eluting stents (DES) over bare
metal stents (BMS) in saphenous vein graft (SVG) percutaneous coronary intervention (PCI), primarily by reducing
target vessel revascularization (TVR) for in-stent restenosis. We compared the outcomes in patients undergoing
SVG stent implantation treated with DES or BMS. In exploratory analyses we investigated the influence of stent
generation and diameter.
Methods. Data were obtained from a prospective database of 657 patients who underwent PCI for SVG lesions
between 2003 and 2011. A total of 344 patients had PCI with BMS and 313 with DES. Propensity scores were developed
based on 15 observed baseline covariates in a logistic regression model with stent type as the dependent
variable. The nearest-neighbour-matching algorithm with Greedy 5-1 Digit Matching was used to produce two patient
cohorts of 313 patients each. We assessed major adverse cardiac events (MACE) out to a median of 3.3 years
(interquartile range: 2.1-4.1). MACE was defined as all-cause mortality, myocardial infarction (MI), TVR and stroke.
Results. There was a significant difference in MACE between the two groups in favour of DES (17.9% DES vs.
31.2% BMS group; p = 0.0017) over the 5-year follow-up period. MACE was driven by increased TVR in the BMS
group. There was no difference in death, MI or stroke. Adjusted Cox analysis confirmed a decreased risk of MACE
for DES compared with BMS 0.75 (95% confidence interval (CI) 0.52-0.94), with no difference in the hazard of allcause
mortality (hazard ratio: 1.08; 95% CI: 0.77-1.68). However, when looking at stent diameters greater than
4 mm, no difference was seen in MACE rates between BMS and DES.
Conclusions. Overall in our cohort of patients who had PCI for SVG disease, DES use resulted in lower MACE rates
compared with BMS over a 5-year follow-up period; however, for stent diameters over 4 mm no difference in
MACE rates was seen.

Keywords

Bare metal stent, Drug-eluting stent, Percutaneous intervention, Stroke, Target vessel revascularisation, Venous graft

2

Article Information

Disclosure

Financial support: No grants or funding have been received for this
study.

Correspondence

Dr. Roshan Weerackody Barts Heart Centre Barts Health NHS Trust West Smithfield EC1A 7BE, London, UK Roshan.weerackody@bartshealth.nhs.uk

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup